Abbott India Limited vs Pfizer Limited
Put two companies head-to-head — source-verified financials and AI-analysed SWOT, together in one view.
Abbott India Limited (Pharmaceuticals) and Pfizer Limited (Pharmaceuticals) go head-to-head here — with source-verified financials and a full SWOT breakdown side by side on Nexvora Intelligence. On the figures reported, Abbott India Limited leads on Revenue (approx.) and Net profit (approx.).
Abbott India Limited leads on Revenue (approx.) and Net profit (approx.).
Choose Abbott India Limited if you prioritize established Indian doctor and pharmacy distribution, recognized chronic and specialty brands, and a focus on higher-margin branded formulations. Choose Pfizer Limited if you value the global Pfizer brand, access to a global product pipeline and regulatory expertise, and exposure to prescription, vaccine, differentiated, and hospital-focused therapies. The right choice depends on whether the buyer prefers Abbott’s domestic branded-formulation strength or Pfizer’s global pipeline and scientific reputation.
Grounded in the verified figures and SWOT shown — guidance, not investment advice.
Head-to-head highlights
| Metric | Abbott India Limited | Pfizer Limited | Basis |
|---|---|---|---|
| Revenue (approx.) | INR 5,800-6,200 crore | Approximately INR 2,000–2,500 crore | AI estimate |
| Net profit (approx.) | INR 1,100-1,300 crore | Approximately INR 400–700 crore | AI estimate |
An arrow marks the larger reported figure — a factual comparison, not a quality judgement. Verified figures come from official filings; AI estimates are approximate and unverified.
Abbott India Limited
Pharmaceuticals · India
Abbott India Limited is an Indian pharmaceutical company and a listed subsidiary of Abbott Laboratories. It markets branded prescription and over-the-counter healthcare products across therapeutic areas such as gastroenterology, women's health, metabolic disorders, central nervous system, pain management, and vaccines.
Verified financials
No source-verified financials available.
Strengths
- Strong parentage from Abbott Laboratories
- Recognized brands in chronic and specialty therapeutic areas
- Established doctor and pharmacy distribution network
- Focus on higher-margin branded formulations
Weaknesses
- High dependence on the Indian domestic pharmaceutical market
- Limited scale compared with India's largest pharma companies
- Exposure to price controls on essential medicines
- Relatively concentrated portfolio in select therapies
Opportunities
- Growth in chronic disease treatment demand in India
- Expansion in women's health, gastroenterology, and metabolic care
- Digital engagement with physicians and patients
- Leveraging Abbott's global portfolio for India-specific launches
Threats
- Intense competition from Indian generic and branded-generic companies
- Regulatory pricing pressure from India's drug price control regime
- Changes in physician prescribing behavior
- Supply chain and input cost volatility
Pfizer Limited
Pharmaceuticals · India
Pfizer Limited is the India-listed subsidiary/affiliate of Pfizer Inc., focused on marketing and distributing prescription medicines, vaccines, and healthcare products in India. Its portfolio spans vaccines, anti-infectives, cardiovascular, pain, women’s health, and specialty therapies.
Verified financials
No source-verified financials available.
Strengths
- Strong global Pfizer brand and scientific reputation
- Access to global product pipeline and regulatory expertise
- Established presence in Indian prescription and vaccine markets
- Portfolio includes differentiated and hospital-focused therapies
Weaknesses
- Dependence on parent-company pipeline and product priorities
- Exposure to Indian drug price controls and regulatory intervention
- Smaller scale than major domestic Indian pharma manufacturers
- Limited manufacturing footprint compared with integrated local competitors
Opportunities
- Rising demand for adult and pediatric vaccination
- Growth in specialty medicines and chronic disease therapies
- Expansion through hospital, institutional, and digital healthcare channels
- Potential introduction of more innovative Pfizer global products in India
Threats
- Intense competition from branded generics and domestic pharma firms
- Government price caps and reimbursement pressure
- Patent expiries and generic substitution
- Regulatory delays or import/manufacturing compliance issues
Frequently asked
Answered from source-verified figures on this page.
Abbott India Limited vs Pfizer Limited: which company leads overall?
Abbott India Limited leads on Revenue (approx.) and Net profit (approx.).
Related market reports
Deep-dive intelligence on the markets these companies compete in.
India Protein Industry Outlook — Intelligence Report
India Pharmaceutical Sector — Intelligence Report
Global Radiopharmaceuticals and Theranostics Market — Intelligence Report
India EV Charging Market — Entry Intelligence Report
AI Analyst
Insights and answers generated live from Abbott India Limited vs Pfizer Limited's verified data. Modeled estimates — not investment advice.